Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 180

Results For "WHO"

2858 News Found

Congenica announces partnership with Avesthagen
Digitisation | August 13, 2022

Congenica announces partnership with Avesthagen

New deal strengthens Congenica’s presence in India


GL Chemtech partners with Edgewater Capital to accelerate growth
News | August 12, 2022

GL Chemtech partners with Edgewater Capital to accelerate growth

Investment in response to increased demand for North American-based chemistry services


S. Sridhar resigns as Managing Director of Pfizer
People | August 11, 2022

S. Sridhar resigns as Managing Director of Pfizer

Sridhar will continue to serve in his current position of Managing Director for as long a period as required until the identification, selection and transition to the new leadership takes place in the company.


Sri Lankan President welcomes opening of free hospital by Sri Sathya Sai Baba Trust
Healthcare | August 10, 2022

Sri Lankan President welcomes opening of free hospital by Sri Sathya Sai Baba Trust

The Sri Sathya Sai Sanjeevani Super Speciality Hospital in Batticaloa will begin its operations by conducting free paediatric cardiac care surgeries and interventions in the next few days


Health-tech startup Clinikk opens 18 primary care centers across Bengaluru and Hyderabad
Startup | August 09, 2022

Health-tech startup Clinikk opens 18 primary care centers across Bengaluru and Hyderabad

Clinikk has raised $6.4 Million so far from marquee investors such as MassMutual Ventures, 500 Startups, Times Internet and prominent angels like Kunal Shah, Rohit MA, Rajan Anandan etc.


JB Pharma records revenue growth of 30% in Q1 FY23
News | August 09, 2022

JB Pharma records revenue growth of 30% in Q1 FY23

Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23


ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer
Drug Approval | August 09, 2022

ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer

Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy


Ube to buy API Corp. from Mitsubishi Chemical
News | August 09, 2022

Ube to buy API Corp. from Mitsubishi Chemical

APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years


Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
Clinical Trials | August 04, 2022

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.


LYNPARZA approved in the EU as adjuvant treatment for early breast cancer
Drug Approval | August 04, 2022

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients